胃癌術後補助化学療法時の栄養介入が予後に与える影響（OGSG1108試験の追加観察研究）

Phase I/II study of neoadjuvant chemoradiotherapy consisting of S-1 and cisplatin for patients with clinically resectable type 4 and large type 3 gastric cancer (OGSG1205)

Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial

Phase II Trial of Capecitabine Plus Bevacizumab for Elderly Patients With Metastatic Colorectal Cancer: OGSG 1102

Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery followed by adjuvant docetaxel and S-1 for patients with large type 3 or type 4 gastric cancer: Short-term outcomes of the phase II OGSG1902 trial

Impact of subsequent chemotherapy after protocol treatment on overall survival in the RINDBeRG trial RINDBeRG試験における後治療の有効性に対する影響

Neoadjuvant chemoradiotherapy for clinical resectable type 4 and large type 3 gastric cancer patient (OGSG1205)

胃癌術後S-1補助化療患者に対する成分栄養剤のアドヒアランスと予後との関連（OGSG1108追加観察研究）

胃癌術後S-1補助化学療法患者に対する成分栄養剤の有用性に関する第Ⅱ相臨床試験(OGSG1108)の追加観察研究

Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)